ArticleDiabetology international2016
Predictive value of titer of GAD antibodies for further progression of beta cell dysfunction in slowly progressive insulin-dependent (type 1) diabetes (SPIDDM).
Article in Diabetology international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Practice guideline: Statement regarding treatment for suspected slowly progressive type 1 diabetes (SPIDDM; probable) cases (English version).Journal of diabetes investigation · 2025Guideline
- Serum-derived microribonucleic acids as potential novel biomarkers for slowly progressive type 1 diabetes mellitus.Journal of diabetes investigation · 2026Article
- COVID-19 infection prior to the onset of type 1 diabetes does not impair beta-cell function: a two-year nationwide follow-up study.BMC endocrine disorders · 2026Observational
- A case of type 1 diabetes mellitus with a single-positive zinc transporter 8 antibody who developed diabetic ketoacidosis during chemotherapy for colorectal cancer.Diabetology international · 2025Article
- A case of latent autoimmune diabetes in the young positive for zinc transporter 8 antibody with type 2 diabetes characteristics.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2025Article
- Update on slowly progressive type 1 diabetes.Journal of diabetes investigation · 2025Article
- Clinical features among adult-onset type 1 diabetes, distribution of subtypes, and differences in probable and definite slowly progressive insulin-dependent diabetes mellitus: A single hospital-based study over a 13-year period.Journal of diabetes investigation · 2025Observational
- Mitochondrial DNA 3243 mutation may be associated with positivity of zinc transporter 8 autoantibody in cases of slowly progressive type 1 diabetes mellitus.Diabetology international · 2025Article
- Practice guideline: Statement regarding treatment for suspected slowly progressive type 1 diabetes (SPIDDM; probable) cases (English Version).Diabetology international · 2025Article
- rs3806265 and rs4612666 of theFrontiers in endocrinology · 2022Article
- Case of slowly progressive type 1 diabetes mellitus with drastically reduced insulin secretory capacity after immune checkpoint inhibitor treatment for advanced renal cell carcinoma.Diabetology international · 2021Article
- Adult-onset autoimmune diabetes: comparative analysis of classical and latent presentation.Diabetology & metabolic syndrome · 2020Article
- Circulating anti-glutamic acid decarboxylase-65 antibody titers are positively associated with the capacity of insulin secretion in acute-onset type 1 diabetes with short duration in a Japanese population.Journal of diabetes investigation · 2019Article
- Slowly Progressive Type 1 Diabetes Mellitus: Current Knowledge And Future Perspectives.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsWhether the titer of glutamic acid decarboxylase antibodies (GADAs), especially a low titer, is a marker of progression of beta cell dysfunction in patients with slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) is unclear. MATERIALS AND
methodsPatients were subdivided as follows: patients with high GADA titers [≥10 U/ml (≥180 WHO U/ml): high GADA] (group 1,
resultsThe proportion of patients progressing to an insulin-dependent state in groups 1, 2, 3 and 4 was significantly higher than in group 5. C-peptide responses in OGTTs of patients in groups 1 and 2 were decreased at a significantly higher rate than in group 5. Multivariate Cox proportional hazard analysis revealed that factors including high GADA, low GADA, onset age <45 years, duration of diabetes <24 months, body mass index (BMI) <22.0 kg/m
conclusionsSPIDDM patients with low GADA titers have a significantly higher risk of progression to an insulin-dependent state than type 2 diabetic patients, suggesting that the presence of GADA, irrespective of the titer, is a hallmark of beta cell failure. Other risk factors for further progression to an insulin-dependent state in SPIDDM patients were ICA, onset age, duration of diabetes, BMI and residual beta cell function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.